IL298148A - Sting agonist combination therapies with immune checkpoint inhibitors - Google Patents
Sting agonist combination therapies with immune checkpoint inhibitorsInfo
- Publication number
- IL298148A IL298148A IL298148A IL29814822A IL298148A IL 298148 A IL298148 A IL 298148A IL 298148 A IL298148 A IL 298148A IL 29814822 A IL29814822 A IL 29814822A IL 298148 A IL298148 A IL 298148A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitor
- sting agonist
- administered
- ctla4
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063025905P | 2020-05-15 | 2020-05-15 | |
| US202063091874P | 2020-10-14 | 2020-10-14 | |
| PCT/US2021/032800 WO2021232019A1 (en) | 2020-05-15 | 2021-05-17 | Sting agonist combination treatments with immune checkpoint inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL298148A true IL298148A (en) | 2023-01-01 |
Family
ID=76306053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298148A IL298148A (en) | 2020-05-15 | 2021-05-17 | Sting agonist combination therapies with immune checkpoint inhibitors |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210380695A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4149457A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2023533111A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230011324A (cg-RX-API-DMAC10.html) |
| CN (1) | CN115803032A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021273508A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3178464A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL298148A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022014110A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021232019A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114940679B (zh) * | 2022-05-23 | 2023-05-16 | 浙江大学医学院附属第四医院 | Sting激动剂前药化合物及其制备方法和应用 |
| WO2024064724A1 (en) * | 2022-09-21 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Compositions and methods for treating cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2935257T3 (es) | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
| JP2016524593A (ja) | 2013-04-29 | 2016-08-18 | メモリアル スローン−ケタリング キャンサー センター | セカンドメッセンジャーのシグナル伝達を変えるための組成物及び方法 |
| EP2996472B1 (en) | 2013-05-18 | 2019-03-27 | Aduro Biotech, Inc. | Compositions and methods for inhibiting "stimulator of interferon gene" dependent signalling |
| CN103908468B (zh) | 2014-04-21 | 2017-02-08 | 上海捌加壹医药科技有限公司 | 环二核苷酸cGAMP在制备抗肿瘤药物中的应用 |
| DK3233882T3 (da) | 2014-12-16 | 2020-01-27 | Kayla Therapeutics | Fluorinerede cykliske dinukleotider til cytokininduktion |
| EP4122492A1 (en) * | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| CN108137641B (zh) | 2015-08-13 | 2022-04-01 | 默沙东公司 | 作为sting激动剂的环状双核苷酸化合物 |
| US20170158772A1 (en) | 2015-12-07 | 2017-06-08 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct - agonist conjugates and methods of use thereof |
| DE212016000029U1 (de) | 2015-12-07 | 2017-07-30 | Opi Vi - Ip Holdco Llc | Zusammensetzungen von Antikörperkonstrukt-Agonist-Konjugaten |
| IL280430B2 (en) * | 2016-03-18 | 2023-11-01 | Univ Texas | Cyclic dinucleotide compounds and methods of use |
| RU2019122598A (ru) | 2016-12-20 | 2021-01-22 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные агонисты sting для лечения рака |
| WO2018118664A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment |
| CA3049791A1 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| AR113224A1 (es) | 2017-04-28 | 2020-02-19 | Novartis Ag | Conjugados de anticuerpo que comprenden un agonista de sting |
| US11466047B2 (en) | 2017-05-12 | 2022-10-11 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| EP3675859A4 (en) | 2017-08-31 | 2021-06-30 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND PROCEDURES FOR TREATMENT OF DISEASES |
| EP3755331B1 (en) | 2018-02-21 | 2026-01-28 | The Scripps Research Institute | Agonists of stimulator of interferon genes (sting) for use in the treatment of cancer |
| JP2023500045A (ja) * | 2019-10-14 | 2023-01-04 | イミューンセンサー セラピューティクス、インコーポレイテッド | Stingアゴニストを用いたがんを処置する方法 |
-
2021
- 2021-05-17 EP EP21730772.7A patent/EP4149457A1/en active Pending
- 2021-05-17 KR KR1020227042332A patent/KR20230011324A/ko active Pending
- 2021-05-17 MX MX2022014110A patent/MX2022014110A/es unknown
- 2021-05-17 WO PCT/US2021/032800 patent/WO2021232019A1/en not_active Ceased
- 2021-05-17 AU AU2021273508A patent/AU2021273508A1/en not_active Abandoned
- 2021-05-17 CA CA3178464A patent/CA3178464A1/en active Pending
- 2021-05-17 US US17/322,827 patent/US20210380695A1/en not_active Abandoned
- 2021-05-17 IL IL298148A patent/IL298148A/en unknown
- 2021-05-17 JP JP2022568780A patent/JP2023533111A/ja active Pending
- 2021-05-17 CN CN202180046447.0A patent/CN115803032A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230011324A (ko) | 2023-01-20 |
| MX2022014110A (es) | 2023-01-30 |
| EP4149457A1 (en) | 2023-03-22 |
| JP2023533111A (ja) | 2023-08-02 |
| US20210380695A1 (en) | 2021-12-09 |
| AU2021273508A1 (en) | 2022-12-15 |
| WO2021232019A1 (en) | 2021-11-18 |
| CA3178464A1 (en) | 2021-11-18 |
| CN115803032A (zh) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrikopoulou et al. | Trastuzumab deruxtecan (DS-8201a): the latest research and advances in breast cancer | |
| Sigalov | A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock | |
| NZ551406A (en) | Treatment of non small cell lung cancer with gemcitabine and erlotinib (an egfr kinase inhibitor) | |
| IL247320B (en) | Use of il -2r beta – selective agonists in combination with anti ctla – 4 or pd - 1 antibodies for treating cancer | |
| CN104684579A (zh) | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 | |
| IL298438A (en) | Therapeutic combinations comprising anti-folr1 immunoconjugates | |
| IL264267A (en) | Radioactive substances that are converted to halogen for the immunization of a modulated cancer vaccine on site | |
| KR20230169462A (ko) | Liv1-adc와 체크포인트 억제제를 사용한 병용 요법 | |
| NZ551431A (en) | Treatment with cisplatin and an EGFR-inhibitor | |
| IL290857B (en) | Oxabicycloheptanes for immune response modulation | |
| Goldwasser et al. | Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients | |
| Sharma et al. | Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC | |
| US20220401556A1 (en) | Use of vdas to enhance immunomodulating therapies against tumors | |
| KR20240130081A (ko) | 항-trop-2 항체-약물 접합체와 추가 치료제의 병용 사용 | |
| WO2021232019A1 (en) | Sting agonist combination treatments with immune checkpoint inhibitors | |
| US20230121320A1 (en) | Sting agonist combination treatments with cytokines | |
| IL297640A (en) | Methods and combinations for cancer treatment using immune checkpoint inhibitor antibodies | |
| IL298155A (en) | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates | |
| US20230270773A1 (en) | Methods of treating cancer with a sting agonist | |
| CN115463217B (zh) | 己酸羟孕酮在增强肿瘤治疗效果中的应用 | |
| JP2026503517A (ja) | Nhl治療薬の製造における抗cd20抗体-薬物コンジュゲートを含む医薬組成物の使用 | |
| HK40087098A (en) | Sting agonist combination treatments with immune checkpoint inhibitors | |
| WO2018148555A1 (en) | Use of vdas to enhance immunomodulating therapies against tumors | |
| McLaughlin et al. | Antibody–Drug Conjugates (ADCs) in clinical development | |
| KR20260057087A (ko) | Steap1xcd3에 결합하는 이중특이적 항체를 이용하여 전립선암을 치료하는 방법 |